{
  "source": "PA-Notification-Actimmune.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1001-13\nProgram Prior Authorization/Notification\nMedication Actimmune® (interferon gamma-1b)\nP&T Approval Date 02/2013, 8/2014, 8/2015, 6/2016, 6/2017, 6/2018, 6/2019, 6/2020, 6/2021,\n6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nActimmune (interferon gamma-1b) is indicated for reducing the frequency and severity of\nserious infections associated with chronic granulomatous disease (CGD). It is also indicated\nfor delaying time to disease progression in patients with severe, malignant osteopetrosis\n(SMO). The National Cancer Comprehensive Network (NCCN) recommends use of\nActimmune in mycosis fungoides (MF) and Sézary syndrome (SS).\nCoverage Information:\nMembers will be required to meet the criteria below for coverage.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Actimmune will be approved based on both of the following criteria:\na. Patient has oncology diagnosis\n-AND-\nb. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Chronic Granulomatous Disease (CGD)\n1. Authorization\na. Actimmune will be approved based on the following criterion:\n(1) Diagnosis of chronic granulomatous disease\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\n2. Reauthorization\na. Actimmune will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Actimmune\nAuthorization will be issued for 12 months.\nC. Osteopetrosis\n1. Initial Authorization\na. Actimmune will be approved based on the following criterion:\n(1) Diagnosis of severe, malignant osteopetrosis\nAuthorization will b",
    "be issued for 12 months.\nC. Osteopetrosis\n1. Initial Authorization\na. Actimmune will be approved based on the following criterion:\n(1) Diagnosis of severe, malignant osteopetrosis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Actimmune will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Actimmune\nAuthorization will be issued for 12 months.\nD. Primary Cutaneous Lymphomas\n1. Initial Authorization\na. Actimmune will be approved based on the following criterion:\n(1) Patient has one of the following diagnoses:\n(a) Mycosis fungoides (MF)\n(b) Sézary syndrome (SS)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Actimmune will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Actimmune\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\n© 2025 UnitedHealthcare Services, Inc.\n2\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class\n• Supply limits may apply.\n4. References:\n1. Actimmune [Package Insert]. Deerfield, IL: Horizon Therapeutics USA Inc.; December 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed April 28, 2025.\nProgram P",
    "ckage Insert]. Deerfield, IL: Horizon Therapeutics USA Inc.; December 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed April 28, 2025.\nProgram Prior Authorization/Notification - Actimmune (interferon gamma-1b)\nChange Control\n8/2014 Annual review with no changes to Coverage Criteria. Updated formatting\nand References.\n8/2015 Annual review. Added oncology indication requirement to age 19 criteria.\nIncreased authorization and reauthorization from 6 months to 12 months\nfor all indications. Updated references.\n6/2016 Annual review. Added reauthorization criteria for CGD. Updated\nformatting and references.\n6/2017 Annual review. Updated references.\n6/2018 Annual review. Updated references.\n6/2019 Annual review. Updated Non-Hodgkin’s Lymphoma to Primary\nCutaneous Lymphomas. Updated references.\n6/2020 Annual review. Updated references.\n6/2021 Annual review. No changes to coverage criteria. Updated background and\nreferences.\n6/2022 Annual review. No changes to coverage criteria. Updated references.\n6/2023 Annual review. No changes to coverage criteria. Added state mandate\nfootnote. Updated reference.\n6/2024 Annual review. No changes to coverage criteria.\n6/2025 Annual review with no changes to coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}